Alicia Gutierrez-Valencia
Overview
Explore the profile of Alicia Gutierrez-Valencia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
388
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trujillo-Rodriguez M, Munoz-Muela E, Serna-Gallego A, Praena-Fernandez J, Perez-Gomez A, Gasca-Capote C, et al.
PLoS One
. 2024 Nov;
19(11):e0314574.
PMID: 39570969
[This corrects the article DOI: 10.1371/journal.pone.0269875.].
2.
Munoz-Muela E, Trujillo-Rodriguez M, Serna-Gallego A, Saborido-Alconchel A, Gasca-Capote C, Alvarez-Rios A, et al.
EBioMedicine
. 2024 Sep;
108:105338.
PMID: 39265504
Background: Among people living with HIV-1 (PHIV), immunological non-responders (INR) experience incomplete immune recovery despite suppressive antiretroviral treatment (ART), facing more severe non-AIDS events than immunological responders (IR) due to...
3.
Saborido-Alconchel A, Serna-Gallego A, Trujillo-Rodriguez M, Munoz-Muela E, Alvarez-Rios A, Lozano C, et al.
Front Immunol
. 2024 Jul;
15:1423734.
PMID: 39055703
Objective: To compare the long-term effects on immune parameters, inflammation, and HIV-1 reservoir after switching to a two-drug (2DR) versus maintaining an integrase inhibitor (InSTI)-based three-drug regimen (3DR). Methods: Cross-sectional...
4.
Mejias-Trueba M, Gutierrez-Valencia A, Llaves-Flores S, Roca-Oporto C, Herrero M, Sotomayor de la Piedra C, et al.
Microbiol Spectr
. 2024 Jun;
12(8):e0065424.
PMID: 38916326
Real-life data on doravirine (DOR) in different drug combinations are limited. We evaluated the effectiveness of DOR plus two nucleos(t)ide reverse transcriptase inhibitors (NRTI), mainly abacavir/lamivudine, and dual therapies in...
5.
Fernandez-Rubio B, Herrera-Hidalgo L, de Alarcon A, Luque-Marquez R, Lopez-Cortes L, Luque S, et al.
Pharmaceutics
. 2023 Dec;
15(12).
PMID: 38140046
Outpatient parenteral antimicrobial therapy (OPAT) is a useful treatment strategy against and other multidrug-resistant bacteria. However, it is hindered by the lack of stability data for the administration of antibiotics...
6.
Alvarez H, Gutierrez-Valencia A, Marino A, Saborido-Alconchel A, Calderon-Cruz B, Perez-Gonzalez A, et al.
Front Immunol
. 2023 Nov;
14:1257725.
PMID: 37920466
Background: Interferon-inducible protein-10 (IP-10) and monokine induced by interferon-gamma (MIG) are chemokines recognized as inflammatory biomarkers during HIV-1 infection. We assessed their early and long-term dynamics after initiation of antiretroviral...
7.
Munoz-Muela E, Trujillo-Rodriguez M, Serna-Gallego A, Saborido-Alconchel A, Ruiz-Mateos E, Lopez-Cortes L, et al.
Biomed Pharmacother
. 2023 Oct;
168:115750.
PMID: 37871555
Background: Dual therapy (DT) has shown comparable results to triple therapy (TT) in efficacy and other immunological aspects. However, there are still some concerns about DT, including several immunological features....
8.
Fernandez-Rubio B, Herrera-Hidalgo L, Lopez-Cortes L, Luque-Marquez R, de Alarcon A, Luque-Pardos S, et al.
J Antimicrob Chemother
. 2023 Aug;
78(10):2451-2456.
PMID: 37574704
Background: Temocillin is an interesting alternative to carbapenems for susceptible Enterobacteriaceae. Although its use in outpatient parenteral antimicrobial therapy (OPAT) programmes has generated interest, this has been hampered by the...
9.
Saborido-Alconchel A, Serna-Gallego A, Lopez-Cortes L, Trujillo-Rodriguez M, Praena-Fernandez J, Dominguez-Macias M, et al.
J Antimicrob Chemother
. 2023 Aug;
78(9):2354-2360.
PMID: 37545387
Background: This was a substudy of a Phase IV, randomized clinical trial (ClinicalTrials.gov identifier: NCT04295460) aiming to compare the activity of dolutegravir/lamivudine versus dolutegravir plus tenofovir alafenamide/emtricitabine (DTG + TAF/FTC)...
10.
Real L, Saez M, Corma-Gomez A, Gonzalez-Perez A, Thorball C, Ruiz R, et al.
iScience
. 2023 Jul;
26(7):107214.
PMID: 37456859
Some HIV controllers experience immunologic progression with CD4 T cell decline. We aimed to identify genetic factors associated with CD4 T cell lost in HIV controllers A total of 561...